The abstract is read at the publisher; the summary is JClub's.
AI-designed 80-amino-acid minibinders targeting human CD20 in CAR T cells yielded 707 CD20-specific enriched designs out of 12,000 submissions, with team hit rates up to 38.4%.
- Why it matters: Protein design evaluations have largely focused on binding affinity, leaving uncertainty about whether de novo binders perform key CAR-T functions like proliferation, cytokine output, and target-specific killing.
- What they did: In the Bits to Binders competition, teams from 42 countries submitted 12,000 de novo CD20 minibinder designs, which were screened by pooled CAR-T proliferation and then validated individually for proliferation, expansion, cytokines, and targeted lysis.
- The result: Common design factors correlated with DNA synthesis, expression, and CD20-specific T cell activation, and applying them as a retrospective filter nearly doubled success rates; the full dataset is released as an open resource.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.